Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep;8(18):1139. doi: 10.21037/atm-20-5586

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2020 Annals of Translational Medicine. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Vitexin treatment was associated with VEGFA-related pathways. (A) Western blot assay for the expression of VEGFA-related pathway proteins (VEGFA, VEGFR2, ERK1/2, p-ERK1/2, p38, and p-p38). (B) Effects of activator skatole treated on pathway proteins. (C) Effects of activator skatole treated on proliferation and apoptosis related proteins. (D) Hoechst staining for the effects of activator skatole treated on apoptosis (magnification ×200). (E) Transwell assay for the effects of activator skatole treated on invasion (magnification ×200). (F) Effects of activator skatole treated on invasion related proteins. (*, P<0.05 vs. control; ^#, P<0.05 vs. skatole treated group).